Main Article Content
Objective: Diabetes mellitus (DM) is a group of metabolic diseases with high blood glucose, which cause the damage and dysfunction of some of the organ systems. Although various oral drugs are used to treat DM, they do not prevent the development of DM related diseases such as nephropathy and retinopathy and glucose dependent vascular diseases. Thus novel strategies for the prevention and treatment of DM are urgently needed. This research aimed to reveal the effects of Thymus Vulgaris Lamiaceae (TVL) and Thymbra Spicata Lamiaceae (TSL) on the damaging effects of DM.
Methods: Prepared TVL and TSL aqueous extracts were studied in the streptozocin induced experimental diabetic rat model. Blood glucose, body weight, and blood biochemical alterations were measured. Rat kidney for nephropathy were enucleated and fixed in paraffin blocks to examine histopathological changes.
Results: Briefly, impaired blood glucose, and weight loss of Diabetic rats were significantly improved by TVL in dose dependent manner (P<0.01). Impaired Blood Uric acid, Urea, and liver enzymes were significantly improved and adjusted to the control group values (P<0.001). The histological analyses of the kidney in TVL and TSL groups revealed the findings of significant healing properties, which was similar to the normal structures of kidney.
Conclusions: In this study, strong biochemical, physiological, and histological improvements in the DM related disorders, such as neuropathy and nephropathy were obtained by TVL treatment.
Rehman HU, Mohammed K. Perioperative management of diabetic patients. Current surgery. 2003;60(6):607-11.
Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World journal of diabetes. 2013;4(3):51-63.
Majeed AA, Mea, Hassan K. Risk Factors for Type 1 Diabetes Mellitus among Children and Adolescents in Basrah. Oman medical journal. 2011;26(3):189-95.
Chen W, Xie A, Chan L. Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Translational research : the journal of laboratory and clinical medicine. 2013;161(4):217-29.
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman medical journal. 2012;27(4):269-73.
Germino FW. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clinical therapeutics. 2011;33(12):1868-82.
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care. 2005;28(1):164-76.
Akkol EK, Avci G, Kucukkurt I, Keles H, Tamer U, Ince S, et al. Cholesterol-reducer, antioxidant and liver protective effects of Thymbra spicata L. var. spicata. Journal of ethnopharmacology. 2009;126(2):314-9.
American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes care. 2010;36:67-74
Harris EH. Elevated Liver Function Tests in Type 2 Diabetes. Clinical Diabetes. 2005;3:115-119.
Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes care. 2004;27 Suppl 1:S79-83.
Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. The New England journal of medicine. 2010;362(12):1090-101.
Wada J, Makino H. Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists. Clinical and experimental nephrology. 2009;13(5):405-14.
Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes research and clinical practice. 2008;82 Suppl 1:S30-7.
Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nature clinical practice Endocrinology & metabolism. 2008;4(8):444-52.
Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrology : JASN. 2008;19(3):433-42.
Kanasaki K, Taduri G, Koya D. Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Frontiers in endocrinology. 2013;4:7.
Meguro S, Shigihara T, Kabeya Y, Tomita M, Atsumi Y. Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects. Internal medicine. 2009;48(9):657-63.
Zhu WW, Chen HP, Ge YC, Xie HL, Zeng CH, Li LS, et al. Ultrastructural changes in the glomerular filtration barrier and occurrence of proteinuria in Chinese patients with type 2 diabetic nephropathy. Diabetes research and clinical practice. 2009;86(3):199-207.
Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. Journal of general internal medicine. 2012;27(4):458-68.
Reddy MA, Tak Park J, Natarajan R. Epigenetic modifications in the pathogenesis of diabetic nephropathy. Seminars in nephrology. 2013;33(4):341-53.
Brenner BM, Hostetter TH, Humes HD. Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. The American journal of physiology. 1978;234(6):F455-60.
Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, et al. Urine biomarkers predict the cause of glomerular disease. Journal of the American Society of Nephrology : JASN. 2007;18(3):913-22.
Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes research and clinical practice. 2009;83(1):1-8.
Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney international. 1997;52(1):111-9.